Free Trial

ORIC Pharmaceuticals (ORIC) News Today

ORIC Pharmaceuticals logo
$5.67 +0.10 (+1.80%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$5.66 0.00 (-0.09%)
As of 05/2/2025 07:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ORIC Pharmaceuticals, Inc. stock logo
Boxer Capital Management LLC Purchases Shares of 1,732,571 ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)
Boxer Capital Management LLC purchased a new position in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 1,732,571 shares of the compa
ORIC Pharmaceuticals (ORIC) Projected to Post Earnings on Monday
ORIC Pharmaceuticals, Inc. stock logo
Adage Capital Partners GP L.L.C. Has $4.04 Million Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)
Adage Capital Partners GP L.L.C. reduced its position in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 13.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 500,000 shares of the company's s
ORIC Pharmaceuticals, Inc. stock logo
ORIC Pharmaceuticals (ORIC) to Release Earnings on Monday
ORIC Pharmaceuticals (NASDAQ:ORIC) will be releasing its Q1 2025 earnings before the market opens on Monday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-5-oric-pharmaceuticals-inc-stock/)
ORIC Pharmaceuticals, Inc. stock logo
Natixis Acquires New Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)
Natixis bought a new position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 79,900 shares of the company's stock, valued at approximately $645,000. Natixis owned abou
ORIC Pharmaceuticals, Inc. stock logo
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Acquired by Silverarc Capital Management LLC
Silverarc Capital Management LLC grew its holdings in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 7.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,178,300 shares of the company
ORIC Pharmaceuticals, Inc. stock logo
Diadema Partners LP Purchases Shares of 214,291 ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)
Diadema Partners LP acquired a new stake in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 214,291 shares of the company's stock, valu
ORIC Pharmaceuticals, Inc. stock logo
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Recommendation of "Buy" from Analysts
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) has received a consensus recommendation of "Buy" from the nine research firms that are covering the company, Marketbeat.com reports. Nine investment analysts have rated the stock with a buy rating. The average 1 year target price among bro
Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals, Inc. stock logo
NEOS Investment Management LLC Purchases Shares of 45,476 ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)
NEOS Investment Management LLC acquired a new position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 45,476 shares of the company's stock,
ORIC Pharmaceuticals, Inc. stock logo
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Rating of "Buy" by Analysts
Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) have been given an average rating of "Buy" by the nine research firms that are currently covering the firm, Marketbeat.com reports. Nine research analysts have rated the stock with a buy recommendation. The average twelve-month p
Oppenheimer Remains a Buy on Zentalis Pharmaceuticals (ZNTL)
ORIC Pharmaceuticals, Inc. stock logo
ORIC Pharmaceuticals (NASDAQ:ORIC) Trading Down 4.9% - Here's What Happened
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 4.9% - What's Next?
ORIC Pharmaceuticals, Inc. stock logo
ORIC Pharmaceuticals (NASDAQ:ORIC) Earns Outperform Rating from Wedbush
Wedbush reiterated an "outperform" rating and set a $20.00 price objective on shares of ORIC Pharmaceuticals in a research note on Thursday.
ORIC Pharmaceuticals, Inc. stock logo
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Rating of "Buy" by Brokerages
Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) have been assigned a consensus recommendation of "Buy" from the nine analysts that are presently covering the firm, Marketbeat.com reports. Nine equities research analysts have rated the stock with a buy recommendation. The avera
ORIC Pharmaceuticals, Inc. stock logo
ORIC Pharmaceuticals (ORIC) to Release Quarterly Earnings on Monday
ORIC Pharmaceuticals (NASDAQ:ORIC) will be releasing earnings before the market opens on Monday, March 10.
ORIC Pharmaceuticals, Inc. stock logo
Wedbush Lifts Earnings Estimates for ORIC Pharmaceuticals
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) - Wedbush lifted their Q1 2025 earnings estimates for ORIC Pharmaceuticals in a research note issued on Tuesday, February 25th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.50) per share for the quarter, up from
ORIC Pharmaceuticals, Inc. stock logo
ORIC Pharmaceuticals (NASDAQ:ORIC) Trading 13.9% Higher on Analyst Upgrade
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 13.9% After Analyst Upgrade
ORIC Pharmaceuticals, Inc. stock logo
ORIC Pharmaceuticals (NASDAQ:ORIC) Receives "Buy" Rating from Guggenheim
Guggenheim reiterated a "buy" rating on shares of ORIC Pharmaceuticals in a research note on Wednesday.
ORIC Pharmaceuticals, Inc. stock logo
ORIC Pharmaceuticals (NASDAQ:ORIC) Price Target Raised to $22.00 at JPMorgan Chase & Co.
JPMorgan Chase & Co. raised their price target on shares of ORIC Pharmaceuticals from $21.00 to $22.00 and gave the stock an "overweight" rating in a report on Wednesday.
Oric Pharmaceuticals (ORIC) Gets a Buy from Oppenheimer
ORIC Pharmaceuticals, Inc. stock logo
HC Wainwright Reaffirms "Buy" Rating for ORIC Pharmaceuticals (NASDAQ:ORIC)
HC Wainwright restated a "buy" rating and issued a $21.00 target price on shares of ORIC Pharmaceuticals in a research note on Friday.
ORIC Pharmaceuticals, Inc. stock logo
Wedbush Expects Reduced Earnings for ORIC Pharmaceuticals
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) - Stock analysts at Wedbush dropped their Q1 2025 earnings per share estimates for shares of ORIC Pharmaceuticals in a research report issued to clients and investors on Tuesday, February 18th. Wedbush analyst D. Nierengarten now forecasts th
ORIC Pharmaceuticals, Inc. stock logo
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up on Earnings Beat
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up on Strong Earnings
ORIC Pharmaceuticals, Inc. stock logo
ORIC Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 5.6% - Should You Sell?
ORIC Pharmaceuticals (NASDAQ:ORIC) Trading Down 5.6% - Here's Why
ORIC Pharmaceuticals, Inc. stock logo
ORIC Pharmaceuticals (NASDAQ:ORIC) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS
ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.01.
Wedbush Sticks to Its Buy Rating for Oric Pharmaceuticals (ORIC)
Oric Pharmaceuticals reports Q4 EPS (51c), consensus (51c)
Oric Pharmaceuticals announces upcoming milestones
Wedbush Remains a Buy on Oric Pharmaceuticals (ORIC)
ORIC Pharmaceuticals, Inc. stock logo
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 6.4% - Time to Sell?
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 6.4% - Should You Sell?
Oric recent weakness a buying opportunity, says JPMorgan
Get ORIC Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter.

ORIC Media Mentions By Week

ORIC Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ORIC
News Sentiment

0.68

0.73

Average
Medical
News Sentiment

ORIC News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ORIC Articles
This Week

6

3

ORIC Articles
Average Week

Get ORIC Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:ORIC) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners